The previous study showed that constitutive activation of NF-κB was characteristic of most ABC subtypes of DLBCL, and the activation of the NF-κB pathway may be one of the mechanisms resulting in drug resistance of relapsed/refractory DLBCL (Turturro, 2015). This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.